Nab-Paclitaxel for Relapsed AIDS-Related Kaposi Sarcoma -A Case Report.

HIV Kaposi sarcoma case report nab-paclitaxel

Journal

Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216

Informations de publication

Date de publication:
2024
Historique:
received: 10 01 2024
accepted: 23 03 2024
medline: 16 4 2024
pubmed: 16 4 2024
entrez: 16 4 2024
Statut: epublish

Résumé

Kaposi sarcoma (KS) incidence has decreased since the initiation of combination antiretroviral therapy (cART), but it remains the most common cancer in people with HIV/AIDS (PWHA). PWHA with advanced immunosuppression who initiate antiretroviral therapy are susceptible to the occurrence of an immune reconstitution inflammatory syndrome (IRIS). This report covers the case of a 25-year-old male with AIDS-related KS who relapsed after Liposomal Doxorubicin, but recovered well after administration of nab-paclitaxel (Nab-PTX). This is a rare case in choosing Nab-PTX to treat relapsed AIDS-KS and get good feedback. We report the case to provide a possible solution to treat AIDS-KS.

Identifiants

pubmed: 38623529
doi: 10.2147/IDR.S456286
pii: 456286
pmc: PMC11017983
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1431-1437

Informations de copyright

© 2024 Yu et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests in this work.

Auteurs

Lele Yu (L)

Department II of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou Sixth People's Hospital, Hangzhou, Zhejiang, 310023, People's Republic of China.

Binhai Zhang (B)

Department II of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou Sixth People's Hospital, Hangzhou, Zhejiang, 310023, People's Republic of China.

Hu Wan (H)

Department II of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou Sixth People's Hospital, Hangzhou, Zhejiang, 310023, People's Republic of China.

Classifications MeSH